BI 811283 is an investigational small-molecule drug developed by the pharmaceutical company Boehringer Ingelheim. It is characterized as a selective inhibitor of polo-like kinase 1 (PLK1), a protein critical for cell division. The compound was investigated for its potential therapeutic application as an antineoplastic agent in the treatment of various cancers.
Mechanism of Action
Polo-like kinase 1 (PLK1) is a serine/threonine kinase that plays an essential role in regulating multiple stages of the cell cycle, particularly mitosis. Its functions include involvement in centrosome maturation, mitotic entry, spindle assembly, chromosome segregation, and cytokinesis. Elevated expression of PLK1 is frequently observed in many human cancers and contributes to uncontrolled cellular proliferation. BI 811283 exerts its effect by specifically inhibiting the enzymatic activity of PLK1. This inhibition disrupts the proper progression of mitosis, leading to mitotic arrest and subsequently inducing apoptosis (programmed cell death) in susceptible cancer cells.
Clinical Development
BI 811283 progressed into clinical trials, where its safety, tolerability, pharmacokinetics, and preliminary efficacy were evaluated in patients with various solid tumors and hematological malignancies. These studies included Phase I and Phase II clinical trials, often investigating its administration as a monotherapy or in combination with standard chemotherapy regimens. Indications explored included non-small cell lung cancer, ovarian cancer, pancreatic cancer, and acute myeloid leukemia, among others.
Current Status
Despite demonstrating initial promise in preclinical studies and some early clinical activity, the extensive clinical development of BI 8111283 appears to have been largely discontinued or not advanced to later-stage Phase III trials for most indications. Factors contributing to such decisions in drug development can include insufficient efficacy in broader patient populations, unacceptable or dose-limiting toxicities, or a less favorable risk-benefit profile compared to other concurrent or emerging therapeutic options.